Biocon Biologics Cited for Ten Issues in Form 483

A host of problems discovered through a July FDA inspection of Biocon Biologics’ Bengaluru, India facility has led to a ten observation Form 483 for the biopharmaceutical company, which produces biosimilars, generic drugs and APIs.
Source: Drug Industry Daily